2025 Review: Building Intelligence and Capacity for Tomorrow’s Cold Chain

By Jay McHarg, CEO, AeroSafe Global

Industry Trends: The Mandate for Transformation

The pharmaceutical landscape is undergoing an irreversible shift, demanding a robust, intelligent, and scalable cold chain infrastructure.

• Market growth: More than 80% of new therapies introduced in the last decade are temperature sensitive, including fast-growing categories like GLP-1s, which have enormous potential across multiple disease states. This surge demands a shift away from fragile logistics models. With cold chain failures still causing 5% product loss, the need for a more reliable, scalable system has never been greater.
• Direct to Patient shift: DTP delivery models are reshaping how therapies are shipped and how patients access care, reducing intermediaries and increasing convenience — but also placing more responsibility directly on the patient. Individuals who are not trained professionals must now trust that their therapy arrived safely and at the right temperature. In a system that fails 5% of the time, this creates risk, anxiety, and a clear need for a more dependable, patient-centered delivery experience.

The industry cannot meet this high-stakes future by relying on 70-year-old technology or high-risk, expensive overnight shipping.

In short, there’s a lot of pressure on an already strained system.

Our Response: Building Intelligence and Capacity

AeroSafe Global’s 2025 strategy was defined by strategic investment to meet this market mandate with a Risk-Free Reuse solution.

A. The Launch of Delivery Intelligence Navigator

The centerpiece of our year was the launch of Delivery Intelligence Navigator, which transformed our logistics from reactive tracking to predictive performance management. This program drove three key metrics for our partners:

1. Guaranteed Compliance: Transforms the “last mile” into the first moment of care by ensuring medications arrive on time, protected, and supported with proactive engagement and visibility.
2. Improved Delivery Performance: Through deep analysis of logistics lane data and delivery patterns we identify failure root causes and implement corrective actions to eliminate recurring issues.
3. Optimized Service Level Agreements: Superior multi-day thermal packaging performance allows partners to confidently shift delivery agreements from expensive Overnight to efficient 2-Day service, driving significant ROI through verifiable cost savings.

B. Tripling Capacity and Responsiveness

Intelligence requires operational scale. In 2025, we successfully tripled our capacity for launching, and supporting our high-performance reusable thermal packaging assets. This expansion ensures:

• Seamless Onboarding: We can meet the high stakes demands of major pharma manufacturers rollouts and product launches with confidence.
• Rapid Responsiveness: Immediate processing and faster deployment times eliminate bottlenecks and guarantee our customers have the assets they need, precisely when they need them.

What We’re Eager to See in 2026

We are actively focused on innovations that will further simplify and enhance the cold chain experience globally.

Smarter, More Predictive Delivery Intelligence We will expand our delivery intelligence platform to include predictive risk modeling, allowing us to identify and prevent cold chain failures before they happen. This will enable even higher reliability at scale and give patients and partners greater confidence in every delivery.

Next-Generation Reusable Systems Designed for Simplicity and Speed: We will introduce new reusable thermal solutions engineered for faster turnaround, lighter materials, and greater flexibility. These systems will further simplify operations, reduce waste, and support a seamless patient delivery experience through the ever expanding delivery channel network.

Enhanced Patient Experience Tools: We will launch new patient-facing digital features that make it easier to track shipments, understand temperature preservation, and gain instant support — reducing uncertainty and improving the first moment of care.

2026 will be the year our proven intelligence and expanded capacity meet new, foundational technology to deliver unprecedented value and sustainability to the pharmaceutical industry.